RecruitingPhase 2NCT06904573

Probiotics in Advanced Urothelial Carcinoma

A Multicenter, Randomized Controlled Phase II Study of Evaluating the Efficacy and Safety of Immunotherapy Combined With Oral Probiotics Compound (Biolosion) in Patients With Advanced Urothelial Carcinoma

Sponsor

Sun Yat-sen University

Enrollment

222 participants

Start Date

Jan 1, 2025

Study Type

INTERVENTIONAL

Conditions

Immunotherapy Advanced Urothelial Carcinoma Probiotics

Summary

This is a multicenter, randomized, controlled phase II Study of evaluating the efficacy and safety of immunotherapy combined with probiotics compound (Biolosion) in patients with advanced urothelial carcinoma.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Cisplatin, a drug called Disitamab vedotin, and others for people with advanced urothelial carcinoma, immunotherapy, and other related conditions. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGProbiotics Compound (Biolosion)

15g, PO, qd

DRUGNab-paclitaxel

230mg/m2, IV, days 1, 8, q3w

DRUGCisplatin

70mg/m2, IV, days 1-3, q3w

DRUGGemcitabine

1.2g/m2, IV, days 1, 8, q3w

DRUGDisitamab vedotin

2.5mg/kg, IV, q2w

DRUGEnfortumab Vedotin

1.25mg/kg, IV, days 1, 8, q3w

DRUGPembrolizumab

200mg, IV, q3w

DRUGToripalimab

240mg, IV, q3w

Locations(3)

Sun yat-sen university cancer center

Guangzhou, Guangdong, China

Sun Yat-sen Memorial Hospital

Guangzhou, Guangdong, China

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

Wuhan, Hubei, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06904573

Related Trials

The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer

NCT067381601 location

Biofield Therapy for the Support of Immunotherapy-related Symptoms Among Adult Cancer Patients - A Pilot Study

NCT075810802 locations

Investigating Real-Time Immunotherapy Symptoms Study

NCT072807151 location

Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)

NCT073274898 locations

Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy

NCT076680371 location